|View printer-friendly version|
|Array BioPharma Announces Pricing of Stock Offering|
|BOULDER, Colo., Feb 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- Array
BioPharma Inc. (Nasdaq: ARRY) today announced the pricing of a public offering
of 3,000,000 shares of its common stock at a price of $10.00 per share. All of
the shares are being offered by Array. In addition, the underwriters will have
an option to purchase up to 450,000 additional shares of common stock from Array
to cover over-allotments, if any. The offering is being made through an
underwriting group managed by Lehman Brothers Inc., and co-managed by UBS
Warburg LLC, Legg Mason Wood Walker, Incorporated and Thomas Weisel Partners
A registration statement relating to these securities was filed with and has been declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of Array BioPharma, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Copies of the final prospectus relating to the offering may be obtained from Lehman Brothers Inc., Prospectus Department, c/o ADP Financial Services, Prospectus Fulfillment, 55 Mercedes Way, Edgewood, NY 11717, telephone: (631) 254-7106, fax: (631) 254-7106.
Array BioPharma is a drug discovery company inventing new small molecule drugs through the integration of chemistry, biology and informatics. Our experienced scientists use our integrated set of drug discovery technologies, which we call the Array Discovery Platform, to invent novel small molecule drugs in collaboration with leading pharmaceutical and biotechnology companies and to build our own pipeline of proprietary drug candidates. For more information on Array BioPharma, please visit our web site at www.arraybiopharma.com .
SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, email@example.com